References
- AmoakuWMThe Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degenerationEye200822864868
- KleinRKleinBECruickshanksKJThe prevalence of age-related maculopathy by geographic region and ethnicityProg Retin Eye Res19991837138910192518
- KleinRKleinBEPrevalence of Age-Related Macular Degeneration in 4 Racial/Ethnic Groups in the multi-ethnic study of atherosclerosisOphthalmol2006113373380
- ShoKTakahashiKYamadaHPolypoidal Choroidal Vasculopathy Incidence, demographic features, and clinical characteristicsArch Ophthalmol20031211392139614557174
- RosenfeldPJBrownDMRanibizumab for Neovascular Age-Related Macular degenerationN Engl J Med20063551419143117021318
- BrownDMMichelsMKaiserPKHeierJSSyJIanchulevTRanibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular degeneration: Two-Year Results of the ANCHOR StudyOphthalmol20091165765
- CookeGLChienABrodskyALeeRCIncidence of hypertrophic scars among African Americans linked to vitamin D-3 metabolism?J Natl Med Assoc2005971004100916080671
- DoDVAntiangiogenic approaches to age-related macular degeneration in the futureOphthalmology200910116Suppl 10S24S2619800536
- SpitzerMSZiemssenFBartz-SchmidtKUGeliskenFSzurmanPTreatment of age- related macular degeneration: focus on ranibizumabClin Ophthalmol2008211419668384
- Schmidt-ErfurthUClinical safety of ranibizumab in age-related macular degenerationExpert Opin Drug Saf2010914916520001757
- GeorgalasIPapaconstantinouDTservakisIKoutsandreaCLadasISevere hypotony and filtering bleb leak after intravitreal injection of ranibizumabTher Clin Risk Manag20095171919436608